Biosimilars, social media among 2015 expected US FDA guidances
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration on 6 January issued its agenda, without specific dates, for new and revised draft guidance documents expected to be issued in 2015 by the agency's Center for Drug Evaluation and Research. They include the much anticipated documents affecting biosimilar products and drug makers' use of social media1.